(Q37809861)

23 August 2017

title

Current and emerging molecular targets in glioma (English)

1 reference

23 August 2017

3

0 references

Gilberto Schwartsmann

6

0 references

author name string

Rafael Roesler

1

1 reference

23 August 2017

André T Brunetto

2

1 reference

23 August 2017

Caroline Brunetto de Farias

4

1 reference

23 August 2017

Algemir Lunardi Brunetto

5

1 reference

23 August 2017

language of work or name

1 reference

1 November 2010

1 reference

Expert Review of Anticancer Therapy

23 August 2017

published in

1 reference

23 August 2017

volume

10

1 reference

23 August 2017

issue

11

1 reference

23 August 2017

page(s)

1735-1751

1 reference

The 2007 WHO classification of tumours of the central nervous system

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Neuro-oncology: the growing role of chemotherapy in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Epidemiology and molecular pathology of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Malignant gliomas in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Development of novel targeted therapies in the treatment of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Malignant astrocytic glioma: genetics, biology, and paths to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Molecularly targeted therapy for malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Mechanisms of disease: the PI3K-Akt-PTEN signaling node--an intercept point for the control of angiogenesis in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

The pharmacology of mTOR inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Targeting the protein kinase C family: are we there yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Classical PKC isoforms in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Targeted therapies for malignant glioma: progress and potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Genome-wide association study identifies five susceptibility loci for glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

U87MG decoded: the genomic sequence of a cytogenetically aberrant human cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Molecular targeted therapies and chemotherapy in malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

New molecular targets in malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Editorial review: targets for glioma treatment: from bench to bedside.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Targeted therapy for malignant glioma patients: lessons learned and the road ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Bevacizumab for malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Phase II trial of gefitinib in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Antiangiogenic therapy for high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Synergistic antiglioma activity of radiotherapy and enzastaurin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Clinical experience of MEK inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Phase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Anaplastic oligodendroglial tumors: a tale of two trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Role of integrin alpha 4 beta 7/alpha 4 beta P in lymphocyte adherence to fibronectin and VCAM-1 and in homotypic cell clustering

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Autocrine and paracrine signaling through neuropeptide receptors in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Neuropeptides as growth factors for normal and cancerous cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

VIP as a trophic factor in the CNS and cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Neurotensin and growth of normal and neoplastic tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

G-protein-coupled receptors and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

New approaches to the therapy of various tumors based on peptide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Bombesin-like peptides and associated receptors within the brain: distribution and behavioral implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Gastrin-releasing peptide receptor as a molecular target for psychiatric and neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Targeting gastrin releasing peptide receptors: New options for the therapy and diagnosis of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Gastrin-releasing peptide receptor content in human glioma and normal brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Functional expression of bombesin receptor in most adult and pediatric human glioblastoma cell lines; role in mitogenesis and in stimulating the mitogen-activated protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Stimulation of proliferation of U138-MG glioblastoma cells by gastrin-releasing peptide in combination with agents that enhance cAMP signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Gastrin-releasing peptide receptors regulate proliferation of C6 Glioma cells through a phosphatidylinositol 3-kinase-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Trk receptors: roles in neuronal signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Expression of p75NGFR trkA, and trkB mRNA in rat C6 glioma and type I astrocyte cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Nerve growth factor (NGF) receptors in a central nervous system glial cell line: upregulation by NGF and brain-derived neurotrophic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Neurotrophin gene expression by cell lines derived from human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Neurotrophic factor expression in childhood low-grade astrocytomas and ependymomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Mitogenesis in glioblastoma multiforme cell lines: a role for NGF and its TrkA receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Control of proliferation and survival of C6 glioma cells with modification of the nerve growth factor autocrine system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

TrkA induces differentiation but not apoptosis in C6-2B glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Growth control of C6 glioma in vivo by nerve growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Nerve growth factor plays a divergent role in mediating growth of rat C6 glioma cells via binding to the p75 neurotrophin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Regulatory effect of nerve growth factor in alpha9beta1 integrin-dependent progression of glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

5-HT2A receptor activation leads to increased BDNF mRNA expression in C6 glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Expression of cannabinoid receptors and neurotrophins in human gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

BDNF and PDE4, but not the GRPR, regulate viability of human medulloblastoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

The p75 neurotrophin receptor is a central regulator of glioma invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Gamma-secretase represents a therapeutic target for the treatment of invasive glioma mediated by the p75 neurotrophin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Glutamate receptor ion channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Glutamate as a therapeutic target in psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

NMDA receptors, place cells and hippocampal spatial memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

The chemical biology of clinically tolerated NMDA receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Extracellular glutamate and other metabolites in and around RG2 rat glioma: an intracerebral microdialysis study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Glutamate release promotes growth of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Autocrine glutamate signaling promotes glioma cell invasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

N-methyl-D-aspartate receptor in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

The NMDA receptor NR2A subunit regulates proliferation of MKN45 human gastric cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Breast cancer expresses functional NMDA receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

The expression of NMDA receptor 1 is associated with clinicopathological parameters and prognosis in the oral squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Glutamate antagonists limit tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

AMPA receptors promote perivascular glioma invasion via beta1 integrin-dependent adhesion to the extracellular matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Attenuated AMPA receptor expression allows glioblastoma cell survival in glutamate-rich environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Metabotropic glutamate receptors: new targets for the control of tumor growth?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Expression of neu/c-erbB-2 in human brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Differences between phosphotyrosine accumulation and Neu/ErbB-2 receptor expression in astrocytic proliferative processes. Implications for glial oncogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

HER-2/neu expression in glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Cyclic AMP and adenyl cyclase in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

The type IV phosphodiesterase inhibitor rolipram induces expression of the cell cycle inhibitors p21(Cip1) and p27(Kip1), resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Phosphodiesterase-4 inhibition and brain tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Epigenetic changes in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Molecular epigenetics and genetics in neuro-oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Identification of human brain tumour initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Cancer stem cells and glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Cancer stem cells and the biology of brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

HER2 as a cancer stem-cell target.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

High-throughput oncogene mutation profiling in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.167

21 January 2018

Identifiers

DOI

10.1586/ERA.10.167

1 reference

23 August 2017

1 reference